Natalia Grullon
Acute Care · Newark, NJNPI 1871216937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,617, more than ten times the $94 reported in 2022. Among acute care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$538
- Astellas Pharma US Inc$496
- Merck$366
- Takeda Pharmaceuticals U.S.A., Inc.$349
- Actelion Pharmaceuticals US, Inc.$281
- Boehringer Ingelheim$240
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,16996%
- Education$1494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 27 | $538 |
| Astellas Pharma US Inc | 20 | $496 |
| Merck | 22 | $366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $349 |
| Actelion Pharmaceuticals US, Inc. | 18 | $281 |
| Boehringer Ingelheim | 15 | $240 |
| GSK | 11 | $191 |
| AstraZeneca | 10 | $171 |
| Amgen | 1 | $125 |
| Cvrx, Inc. | 1 | $124 |
| Viatris Specialty LLC | 5 | $97 |
| Mylan Specialty L.p. | 4 | $74 |
| Bayer | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 3 | $42 |
| Vifor Pharma, Inc. | 2 | $34 |
| Harmony Biosciences LLC | 2 | $30 |
| Atricure, Inc. | 1 | $30 |
| Pulmonx Corporation | 1 | $23 |
| Electromed, Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Pfizer | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$125
- TYVASO$125
- Barostim Neo System$124
- LIVTENCITY$121
How this compares
$3,318 in reported general payments places this provider in the 90th percentile of 656 acute care providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 23 | $11,934 |
| Tacrolimus | 100 | $6,291 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,595 |
| Mycophenolate Mofetil | 32 | $2,215 |
| Prednisone | 79 | $1,252 |
| Dapsone | 12 | $609 |
| Pantoprazole Sodium | 55 | $390 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 75 | $358 |
| Pravastatin Sodium | 35 | $209 |
| Azithromycin | 43 | $204 |
| Atorvastatin Calcium | 14 | $164 |
| Folic Acid | 16 | $146 |
| Alendronate Sodium | 20 | $125 |
| Levetiracetam | 12 | $122 |
| Escitalopram Oxalate | 15 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $191 | $4,59512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 656 acute care providers in New Jersey.
Other acute care in Newark
- Jennifer McCarthyNewark$16K
- Danielle ConstandisNewark$7K
- Rebeca IztuetaNewark$4K
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Hanane ChaibainouWestampton$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.